Recombinant bacillus calmette-guerin vaccine strain with over-expression mycobacterium tuberculosis Rv3586 and application of recombinant bacillus calmette-guerin vaccine strain

A technology of Mycobacterium tuberculosis and recombinant BCG, applied in the field of tuberculosis vaccine

CN106479946AActive Publication Date: 2017-03-08FOURTH MILITARY MEDICAL UNIVERSITY
3 Cites 3 Cited by

Patent Information

Authority / Receiving Office
CN · China
Current Assignee / Owner
Publication Date
2017-03-08

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

The invention relates to a recombinant bacillus calmette-guerin vaccine strain with over-expression mycobacterium tuberculosis Rv3586 and application of the recombinant bacillus calmette-guerin vaccine strain. Plasmids with encoding genes of the mycobacterium tuberculosis Rv3586 are transformed into bacillus calmette-guerin vaccine, and the recombinant bacillus calmette-guerin vaccine strain can be obtained by means of screening, is called as Bacillus calmette-Guerin rBCG-DisA and is called as rBCG-DisA for short, and a preservation number of the bacillus calmette-guerin vaccine strain is CCTCC M 2016335. The recombinant bacillus calmette-guerin vaccine strain and the application have the advantages that the recombinant bacillus calmette-guerin vaccine strain with the over-expression mycobacterium tuberculosis Rv3586 has merits of target antigens and bacillus calmette-guerin vaccine and can be used for individual immunization, or booster immunization can be carried out by the recombinant bacillus calmette-guerin vaccine strain and mycobacterium tuberculosis Ag85B-ESAT6 subunit vaccine, high immune response of normal and affected mice can be induced, the mycobacterium-resistant protective ability of organisms can be improved, and accordingly the recombinant bacillus calmette-guerin vaccine strain has an excellent application prospect.
Need to check novelty before this filing date? Find Prior Art

Description

technical field

[0001] The invention belongs to the field of tuberculosis vaccines. The invention relates to a recombinant BCG strain overexpressing Mycobacterium tuberculosis Rv3586. The present invention also relates to the application of the recombinant BCG strain alone or in combination with the subunit vaccine Ag85B-ESAT6 (AE) in tuberculosis preventive and therapeutic vaccines and preparations. Background technique

[0002] Tuberculosis Epidemic Status

[0003] Tuberculosis (TB) is still the most serious infectious disease worldwide. Mycobacterium tuberculosis (Mtb) is the pathogen of TB, and about 1 / 3 of the world's population has been infected with Mtb. According to the 2014 WHO report, there were approximately 9.6 million new TB cases worldwide. my country is one of the 22 countries with a high TB ​​burden in the world. In 2014, the number of new TB patients in my country was 930,000, ranking third in the world after India and Indonesia. The incidence of TB is ...

Examples

Embodiment Construction

[0044] Construction of Rv3586 Escherichia coli-Mycobacterium Shuttle Expression Vector

[0045] Primers were designed according to the genome Rv3586 gene sequence of the Mtb H37Rv strain:

[0046] P1: 5'-tttaagcttatgcacgctgtgactcgtccgacc-3' HindIII site

[0047] P2: 5'-gcgaagcttaaggcggataattattgatcgc-3' HindIII site

[0048] Primers were synthesized by Shanghai Sangon Biotechnology Co., Ltd. Use the genomic DNA of Mtb H37Rv strain as a template to amplify the target gene by PCR. Reaction parameters: pre-denaturation at 95°C for 5 minutes, denaturation at 95°C for 30 seconds, renaturation at 57°C for 1 minute, extension at 72°C for 100 seconds, 35 cycles, and extension at 72°C for 5 minutes after the last cycle . 1% agarose gel electrophoresis analysis showed that a 1 100bp target band was amplified ( figure 1 ). The target fragment was recovered by the gel recovery kit, digested with HindIII, and the digested product was recovered by 1% agarose gel electrophoresis. T4 DN...